Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shares were down 1.9% on Monday . The company traded as low as $7.24 and last traded at $7.37, with a volume of 3,063,112 shares. The stock had previously closed at $7.51.

A number of research analysts recently weighed in on ARIA shares. Jefferies Group reissued a “buy” rating and set a $13.00 target price on shares of Ariad Pharmaceuticals in a report on Wednesday, June 22nd. JMP Securities reissued a “buy” rating on shares of Ariad Pharmaceuticals in a report on Monday, June 6th. Royal Bank Of Canada reissued a “hold” rating on shares of Ariad Pharmaceuticals in a report on Monday, June 20th. Cowen and Company reissued an “outperform” rating and set a $10.00 target price on shares of Ariad Pharmaceuticals in a report on Thursday, May 19th. Finally, William Blair reissued a “buy” rating and set a $10.00 target price on shares of Ariad Pharmaceuticals in a report on Tuesday, May 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. Ariad Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $9.06.

The company’s market capitalization is $1.41 billion. The firm’s 50 day moving average price is $7.91 and its 200-day moving average price is $6.60.

Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings results on Tuesday, May 10th. The pharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.04. The business had revenue of $35.60 million for the quarter, compared to analysts’ expectations of $43.06 million. The business’s revenue was up 48.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.28) earnings per share. Analysts anticipate that Ariad Pharmaceuticals Inc. will post ($0.60) earnings per share for the current year.

In other Ariad Pharmaceuticals news, SVP Hugh M. Cole sold 6,012 shares of the firm’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $7.05, for a total value of $42,384.60. Following the completion of the sale, the senior vice president now directly owns 29,262 shares of the company’s stock, valued at $206,297.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Athanese Lavidas sold 76,250 shares of the firm’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $8.21, for a total value of $626,012.50. Following the completion of the sale, the director now directly owns 141,631 shares of the company’s stock, valued at $1,162,790.51. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in Ariad Pharmaceuticals by 7.8% in the fourth quarter. Rhumbline Advisers now owns 174,193 shares of the pharmaceutical company’s stock worth $1,089,000 after buying an additional 12,560 shares in the last quarter. ProShare Advisors LLC increased its stake in Ariad Pharmaceuticals by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 176,600 shares of the pharmaceutical company’s stock worth $1,104,000 after buying an additional 16,552 shares in the last quarter. New York State Common Retirement Fund increased its stake in Ariad Pharmaceuticals by 18.0% in the fourth quarter. New York State Common Retirement Fund now owns 193,180 shares of the pharmaceutical company’s stock worth $1,207,000 after buying an additional 29,480 shares in the last quarter. California State Teachers Retirement System increased its stake in Ariad Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 310,276 shares of the pharmaceutical company’s stock worth $1,939,000 after buying an additional 5,000 shares in the last quarter. Finally, Oxford Asset Management increased its stake in Ariad Pharmaceuticals by 60.9% in the fourth quarter. Oxford Asset Management now owns 476,178 shares of the pharmaceutical company’s stock worth $3,012,000 after buying an additional 180,186 shares in the last quarter.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.